Press Release

MONTREAL, October 15, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, presented updated clinical data showing achievement of functional cure of HBV and HDV infections with REP 2139-based combination therapy at the “Antivirals: Targeting HBV and Beyond” symposium at the 2018 Discovery on Target Meeting held on September 25th in Boston, MA, USA ( and at the 2018 HBV International Meeting held October 3-6th in Taormina, Italy (

Replicor’s presentations updated the continually evolving data on the establishment of functional cure of HBV and HDV infection with REP 2139, which highlighted the establishment of long-term functional control of HBV and HDV infection which no longer requires therapy and is accompanied by reversal of liver dysfunction. In the latest REP 401 study, 48 weeks of triple combination therapy with tenofovir disoproxil fumarate, pegylated interferon and REP 2139-Mg has currently allowed 85% of patients to achieve this goal, with 41% of these additionally achieving functional cure (no detectable HBV DNA or HBsAg).

Dr. Vaillant, CSO of Replicor commented, “These data cement in place not only the critical importance of HBsAg clearance in restoring immune function, but also that when this clearance is very efficient (> 4 log10 from baseline), the restoration of functional control and functional cure with immunotherapy is much more easily achieved. These reliable effects with REP 2139-Mg pave the way for us to examine combination regimens with other immunotherapies, which have the potential to both increase response rates and even shorten therapy”.

Additional pre-clinical mechanistic data confirming the ability of REP 2139 to target assembly and release of HBV subviral particles (the main source of HBsAg in the blood) was also presented.

These presentations can be downloaded at

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at

Media Contact:
Natacha Dorget
(514) 733-1998